Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3442 clinical trials
Neo-TACE-HAIC for BCLC B Stage HCC (Neoconcept)

Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although BCLC (Barcelona clinical liver cancer) system recommend to transarterial chemoembolization (TACE) for BCLC B stage patients, increasing studies suggested that hepatic resection provided survival benefit for those patients. However, a relative high recurrence risk leads surgeons to …

folfox regimen
liver cancer
hepatocellular carcinoma
hepatic arterial infusion
chemoembolization
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma

This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

liver cancer
vaccination
hepatocellular carcinoma
apatinib
MRI
  • 0 views
  • 16 Feb, 2024
  • 1 location
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma

This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.

radiofrequency ablation
hepatocellular carcinoma
stereotactic body radiation therapy
recurrent hepatocellular carcinoma
carcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
Role of CEUS as a Secondary Diagnostic Modality

To determine the role of contrast-enhanced ultrasound (CEUS) as a second-line imaging modality after gadoxetate-enhanced MRI (Gd-EOB-MRI) for identifying hepatocellular carcinoma (HCC) among at-risks observations.

hepatocellular carcinoma
contrast-enhanced ultrasound
carcinoma
  • 0 views
  • 05 Aug, 2020
Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, with more than 700,000 new cases in the world every year. China has the highest incidence and death rate of HCC in the world, accounting for 55% of the world's annual incidence and 45% of the world's annual deaths. …

metastasis
hepatocellular carcinoma
anticoagulants
stroke
postoperative complications
  • 0 views
  • 16 Feb, 2024
  • 1 location
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected …

liver mri
liver cancer
hepatocellular carcinoma
hypertension
cirrhosis
  • 0 views
  • 16 Feb, 2024
  • 10 locations
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for patients with advanced hepatocellular carcinoma.

lenvatinib
hepatocellular carcinoma
measurable disease
carcinoma
  • 0 views
  • 05 Aug, 2020
Irreversible Electroporation of Unresectable Liver Tumors

The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.

metastasis
liver tumor
biliary tract cancer
cancer
irreversible electroporation
  • 0 views
  • 05 Aug, 2020
Preliminary Antitumor Activity Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

The primary objective of this study is to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

metastatic hepatocellular carcinoma
liver cancer
hepatocellular carcinoma
lenvatinib
unresectable hepatocellular carcinoma
  • 0 views
  • 05 Aug, 2020
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing …

metastasis
monoclonal antibodies
non-small cell lung cancer
melanoma
stage iv nsclc
  • 0 views
  • 16 Feb, 2024
  • 9 locations